# Project Glioblastoma CARE: Cellular Analysis of Resistance and Evolution (2)

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2021 · $299,999

## Abstract

Project Glioblastoma CARE: “Cellular Analysis of Resistance and Evolution”. Proposal for Year 3
extension.
Abstract
High grade gliomas (HGG/GBM) across the pediatric, adolescent and young adult (AYA), and adult
populations represent a common unmet therapeutic need underpinned by the cellular heterogeneity of
these tumors and its contribution to treatment resistance and residual disease, the ultimate cause of
death. Despite numerous molecular studies across this age spectrum, high grade glioma and
glioblastoma at recurrence remain poorly characterized, despite being the context for most clinical
trials. This project leverages multi-institutional specimen cohorts that addresses the limited availability of
paired longitudinal patient specimens and combines such cohorts with state-of-the-art single-cell
platforms to profile adult and pediatric gliomas through recurrence. This effort represents a first in kind
continuum of research initiative across the pediatric, AYA, adult HGG/GBM landscape with Project HOPE
(Pediatric and AYA High-Grade Glioma Omics Project) representing the pediatric/AYA effort, and
Project CARE (cellular analysis of resistance and evolution) representing the adult effort. Our
central hypothesis is that the interplay between genetic, TME interactions and epigenetic
diversity drive cellular plasticity and fuels gliomas adaptation to therapy and intra-tumoral
phenotypic heterogeneity. To address this, we will tackle the integration of genetic, epigenetic, and
phenotypic heterogeneity across IDH-wildtype GBM and IDH-mutant gliomas clinical samples, with the
following three independent yet interrelated aims: examine the role of epigenetic alterations, such as
aberrant DNA methylation, in cellular programs driving GBM resistance to therapy (Aim 1); define the
impact of somatic mutations as a function of GBM cellular states and their role in driving resistance
(Aim 2); expand our cohort to additional classes of disease, namely interrogate primary and recurrent
IDH-mutant gliomas (Aim 3).

## Key facts

- **NIH application ID:** 10415597
- **Project number:** 3P30CA006516-56S6
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** LAURIE Hollis GLIMCHER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $299,999
- **Award type:** 3
- **Project period:** 1997-03-10 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10415597

## Citation

> US National Institutes of Health, RePORTER application 10415597, Project Glioblastoma CARE: Cellular Analysis of Resistance and Evolution (2) (3P30CA006516-56S6). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10415597. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*